BMO Capital lowered the firm’s price target on Neurocrine to $100 from $111 and keeps a Market Perform rating on the shares. Failure in both FOS and anhedonia Phase 2 trials will likely reset investor expectations for the company following a positive Q3 report, the analyst tells investors in a research note. Coinciding with these announced failures, the management has indicated they are continuing to review whether there may be any impacts to ‘352’s ongoing SCN8A epilepsy trial, potentially suggesting additional discontinuations, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target lowered to $114 from $116 at Mizuho
- Neurocrine price target lowered to $137 from $145 at BofA
- Neurocrine price target lowered to $125 from $135 at Barclays
- Xenon reports Neurocrine will not continue development of NBI-921352
- Neurocrine reports positive results of Ingrezza in chorea study